Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions

Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00847860

Acronym

CAVAD

Enrollment

200

Registered

2009-02-19

Start date

2008-03-31

Completion date

2011-06-30

Last updated

2015-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke, Vascular Dementia

Keywords

cognition

Brief summary

The purpose of this study is to evaluate the efficacy of PDE-3 inhibitor, cilostazol, in prevention and treatment of vascular dementia, in those with brain white matter lesions and vascular risk factors.

Interventions

DRUGCilostazol

Cilostazol 100 mg bid for 12 months

DRUGAspirin

Aspirin 100 mg qd for 12 months

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

40 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. Age ranging from 40 to 80 years 2. After newly ischemic stroke from 3 months to 2 years 3. Brain CT or MRI shows stroke lesions and white matter lesions, ARWMC(Age Related White Matter Change)\>=4 4. Moderate or mild cognitive deficits: MMSE 12-26 5. Vascular or mixed dementia: Hachinski ischemic score\>4 6. Moderate or mild disability: MRS\<=4,NIHSS\<20 7. Informed consent

Exclusion criteria

1. Definitive diagnosis of dementia prior to the stroke 2. Cerebral hemorrhage in the past 3. Cerebral embolism result from cardiogenic embolus 4. Critically ills: MRS\>4,NIHSS\>=20 5. Bed-ridden patient who is hardly discovered newly stroke 6. patient with sever cardiac, hepatic or nephric complication 7. dementia caused not by vascular lesions 8. other diseases disturb the cognitive evaluation 9. susceptibility to varieties of allergen 10. abstain from Cilostazol or Asprin 11. antiplatelet treatment, anticoagulation or fibrinolysis are needed because of other diseases 12. rejected to participate by the patient or the family

Design outcomes

Primary

Measure	Time frame
changes of the scores of MMSE, MOCA,CDR,and Blessed-Roth	one year

Secondary

Measure	Time frame
stroke recurrence, other vascular ischemic events, bleeding events	one year

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026